BiotechTube
ReCor Medical

ReCor Medical

Palo Alto, United States· Est.
recormedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $235M

Overview

ReCor Medical is a private, commercial-stage medical device company pioneering ultrasound-based renal denervation (RDN) for the treatment of hypertension. Its Paradise uRDN System is supported by a robust clinical program, including the global RADIANCE trials, demonstrating significant and sustained blood pressure reductions. The company is positioned to address a large, underserved market of patients with uncontrolled hypertension despite medication, offering a one-time, minimally invasive procedural solution.

CardiovascularHypertension

Technology Platform

Ultrasound-based renal denervation (uRDN) using a catheter-delivered, 360-degree ultrasound energy system (Paradise) to ablate renal nerves for blood pressure reduction.

Funding History

4
Total raised:$235M
Series D$95M
Series C$75M
Series B$40M
Series A$25M

Opportunities

The global hypertension market represents a massive, underserved patient population, particularly those with resistant hypertension.
FDA approval provides access to the large U.S.
market, and strong long-term clinical data supports durability of effect, aiding adoption and reimbursement.
The platform technology has potential for expansion into other sympathetic-driven conditions like heart failure.

Risk Factors

Commercial success depends on overcoming market education challenges post-prior RDN setbacks and securing broad physician adoption and reimbursement.
The company faces competition from other RDN devices and pharmaceutical therapies.
As a private company commercializing a capital-intensive device, execution risk and funding needs are significant.

Competitive Landscape

ReCor competes in the renal denervation space primarily against radiofrequency-based RDN systems from large medtech players like Medtronic (Symplicity Spyral) and Abbott (formerly St. Jude Medical). Competition also includes intense pharmacological R&D for hypertension and the entrenched standard of care, which is drug therapy. ReCor differentiates with its ultrasound-based, circumferential energy delivery platform.

More companies in Digital Health & Biotech SaaS →More companies in United States →